Welcome to our dedicated page for Mastercard news (Ticker: MA), a resource for investors and traders seeking the latest updates and insights on Mastercard stock.
Mastercard Incorporated reports developments tied to its global digital payments network, financial results, investor events, customer partnerships, and payments research. The company supports digital payment choices in more than 200 countries and territories, using its technology, partnerships, and networks to serve consumers, businesses, financial institutions, and governments.
Recurring news themes include quarterly earnings releases and conference calls, participation in investor conferences, card-program relationships on the Mastercard network, and regional studies on digital payments, security, trust, and financial inclusion.
Mastercard (NYSE: MA) will release its second quarter 2026 financial results on Thursday, July 30, 2026. A conference call to discuss the results starts at 9:00 a.m. Eastern Time, with webcast and dial-in access plus a 30-day replay via investor.mastercard.com.
Mastercard (NYSE: MA) announced that its Board of Directors declared a quarterly cash dividend of $0.87 per share.
The dividend will be paid on August 7, 2026 to holders of Class A and Class B common stock of record as of July 9, 2026.
Mastercard (NYSE:MA) reported results of its annual meeting of stockholders held June 16, 2026. All 11 directors were elected for one-year terms, executive officer compensation was approved on an advisory basis, and PricewaterhouseCoopers was ratified as independent auditor for 2026. Two stockholder proposals were not approved. Final voting results will be filed on Form 8-K and posted on Mastercard's investor relations site.
Summary not available.
Mastercard (NYSE:MA) announced multiple leadership changes effective August 3, 2026, aimed at aligning its organization with customer needs and supporting continued growth.
Key updates include a new CFO, a new Chief Business Officer, expanded commercial payments leadership, and role shifts for several senior executives, plus a planned retirement.
Mastercard (NYSE: MA) announced participation in two June 2026 investor conferences. Executives will discuss network, real-time payments and security solutions, as well as broader product topics.
Both sessions will be webcast live, with replays available for 30 days on Mastercard's investor website.
Mastercard (NYSE:MA) announced that Mastercard Transaction Services (U.S.) has been granted a BitLicense by the New York State Department of Financial Services. The license recognizes Mastercard’s work with regulators and its focus on security, compliance and risk management in digital assets.
The approval supports Mastercard’s long-term strategy to engage with evolving payment and settlement infrastructure for digital currencies, including stablecoins and tokenized deposits, while maintaining standards used in its global payments network.
Mastercard (NYSE:MA) is powering Amazon's new Prime Business and Amazon Business credit cards, issued by U.S. Bank. The cards offer up to 5% back on eligible Amazon and travel purchases, 2% back in top non-Amazon categories, flexible 0% equal monthly installments, and built-in spend management tools—without annual or foreign transaction fees.
Recorded Future (NYSE: MA) announced it was named a Leader in the 2026 Gartner Magic Quadrant for Cyberthreat Intelligence Technologies on May 4, 2026. The company cited its intelligence‑first platform, the Intelligence Graph® (200+ billion nodes), and coverage across adversaries, infrastructure, and targets.
Recorded Future serves over 1,900 organizations in 80 countries and notes it was acquired by Mastercard in 2024.
Knoa Pharma (V) began operations on May 1, 2026 as a public health–focused pharmaceutical company wholly owned by the not‑for‑profit Knoa Foundation (a 501(c)(4)).
The company will manufacture existing medicines, including opioid analgesics, under a strict operating injunction with independent monitoring, will not promote opioid products, and will use value generated to fund opioid abatement and no‑profit access to overdose reversal and OUD treatments.